Proposed Collection; 60-day Comment Request: A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph) (NCI), 52325-52326 [2015-21273]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices
Opportunity on (301) 458–4EEO (4336)
as soon as possible.
Dated: August 24, 2015.
James Scanlon,
Deputy Assistant Secretary for Planning and
Evaluation (Science and Data Policy), Office
of the Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2015–21328 Filed 8–27–15; 8:45 am]
BILLING CODE 4151–05–P
Bethesda, MD 20899823, (240) 669–5062,
wurstera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 25, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–21378 Filed 8–27–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
National Institutes of Health
Lhorne on DSK5TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation (R01).
Date: September 22, 2015.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G33, 5601 Fishers Lane, Rockville, MD
20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G33B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20899823, (240) 669–5062,
wurstera@mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: September 25, 2015.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G33, 5601 Fishers Lane, Rockville, MD
20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G33B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
VerDate Sep<11>2014
14:19 Aug 27, 2015
Jkt 235001
Proposed Collection; 60-day Comment
Request: A Multi-Center International
Hospital-Based Case-Control Study of
Lymphoma in Asia (AsiaLymph) (NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute, the National
Institutes of Health (NIH) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited to address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Nathaniel Rothman,
Senior Investigator, Division of Cancer
Epidemiology and Genetics, 9609
Medical Center Drive, MSC 9776, Room
6E134, Bethesda, Maryland 20892 or
call non-toll-free number (240) 276–
7169 or Email your request, including
SUMMARY:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
52325
your address to: rothmann@
mail.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: A Multi-Center
International Hospital-Based CaseControl Study of Lymphoma in Asia
(AsiaLymph) (NCI), 0925–0654,
Expiration Date 10/31/2015–REVISION,
National Institutes of Health (NIH).
Need and Use of Information
Collection: Incidence rates of certain
lymphomas have increased in the
United States and in many other parts
of the world. The contribution of
environmental, occupational, and
genetic factors to the cause of
lymphoma and leukemia has generated
a series of novel findings from
epidemiological studies conducted in
the United States that have attempted to
explain this increase. However, none of
the chemical associations have been
conclusively established and the
identification of the key, functional
alleles in gene regions associated with
risk of lymphoma requires further
elucidation. Further, the ability to
follow-up, confirm, and extend these
observations in the United States is
limited by the low prevalence and
limited range of several important
chemical and viral exposures and the
high to complete linkage disequilibrium
among key candidate genetic loci in
Western populations. To optimize the
ability to build on and clarify these
findings, it is necessary to investigate
populations that differ from those in the
West in both exposure patterns and
underlying genetic structure. A
multidisciplinary case-control study of
lymphoma in Asia, where lymphoma
rates have also risen, provides an
opportunity to replicate and extend
recent and novel observations made in
studies in the West in a population that
is distinctly different with regard to
patterns of key risk factors, including
range of exposures, prevalence of
exposures, correlations between
exposures, and variation in gene regions
of particular interest. It will also
improve the ability to understand the
causes of certain types of rare
lymphoma tumors in the United States
that occur at much higher rates in Asia.
As such, AsiaLymph will confirm and
extend previous findings and yield
novel insights into the causes of
lymphoma and leukemia in both Asia
and in the United States. The major
postulated risk factors for evaluation in
this study are chemical exposures (i.e.,
E:\FR\FM\28AUN1.SGM
28AUN1
52326
Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices
participating hospitals will be screened
and enrolled. There will be a one-time
computer-administered interview, and
patients will also be asked to provide a
one-time blood and buccal cell mouth
wash sample and lymphoma cases will
organochlorines, trichloroethylene, and
benzene) and genetic susceptibility.
Other factors potentially related to
lymphoma, such as viral infections,
ultraviolet radiation exposure, medical
conditions, and other lifestyle factors
will also be studied. Patients from 11
be asked to make available a portion of
their pathology sample.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,086.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Frequency of
response
Time per
response
(hours)
Annual burden
hours
Types of respondents
Instrument
Potential Study Subjects
Consented Patient
Cases.
Consented Patient Controls.
Study Pathologists .........
Interviewers ...................
Screening Questions ...........................................
Core Questionnaire & Occupational Job Module
1,804
967
1
1
5/60
105/60
150
1,692
Core Questionnaire & Occupational Job Module
300
1
105/60
525
Pathology sample request and tracking form .....
Tracking forms .....................................................
10
15
97
85
5/60
30/60
81
638
Dated: August 24, 2015.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, NIH.
[FR Doc. 2015–21273 Filed 8–27–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on
September 28, 2015. The topic for this
meeting will be ‘‘New Opportunities for
Clinical Research on Type 2 Diabetes.’’
The meeting is open to the public.
DATES: The meeting will be held on
September 28, 2015 from 1:00 p.m. to
4:30 p.m. Individuals wanting to present
oral comments must notify the contact
person at least 10 days before the
meeting date.
ADDRESSES: The meeting will be held in
the Democracy 2 Building at 6707
Democracy Blvd., Bethesda, MD, in
Conference Room 701.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, see the DMICC Web site,
www.diabetescommittee.gov, or contact
Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A19, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–496–6623; FAX:
301–480–6741; email: dmicc@
mail.nih.gov.
Lhorne on DSK5TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:19 Aug 27, 2015
Jkt 235001
The
DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
September 28, 2015 DMICC meeting
will focus on New Opportunities for
Clinical Research on Type 2 Diabetes.
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 10
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
Web site, www.diabetescommittee.gov.
Dated: August 21, 2015.
B. Tibor Roberts,
Executive Secretary, DMICC, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of
Health.
[FR Doc. 2015–21291 Filed 8–27–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 80, Number 167 (Friday, August 28, 2015)]
[Notices]
[Pages 52325-52326]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-21273]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-day Comment Request: A Multi-Center
International Hospital-Based Case-Control Study of Lymphoma in Asia
(AsiaLymph) (NCI)
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Cancer Institute,
the National Institutes of Health (NIH) will publish periodic summaries
of proposed projects to be submitted to the Office of Management and
Budget (OMB) for review and approval.
Written comments and/or suggestions from the public and affected
agencies are invited to address one or more of the following points:
(1) Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) The quality, utility, and clarity of the information to be
collected; and (4) Minimize the burden of the collection of information
on those who are to respond, including the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology.
To Submit Comments and for Further Information: To obtain a copy of
the data collection plans and instruments, submit comments in writing,
or request more information on the proposed project, contact: Nathaniel
Rothman, Senior Investigator, Division of Cancer Epidemiology and
Genetics, 9609 Medical Center Drive, MSC 9776, Room 6E134, Bethesda,
Maryland 20892 or call non-toll-free number (240) 276-7169 or Email
your request, including your address to: rothmann@mail.nih.gov. Formal
requests for additional plans and instruments must be requested in
writing.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Proposed Collection: A Multi-Center International Hospital-Based
Case-Control Study of Lymphoma in Asia (AsiaLymph) (NCI), 0925-0654,
Expiration Date 10/31/2015-REVISION, National Institutes of Health
(NIH).
Need and Use of Information Collection: Incidence rates of certain
lymphomas have increased in the United States and in many other parts
of the world. The contribution of environmental, occupational, and
genetic factors to the cause of lymphoma and leukemia has generated a
series of novel findings from epidemiological studies conducted in the
United States that have attempted to explain this increase. However,
none of the chemical associations have been conclusively established
and the identification of the key, functional alleles in gene regions
associated with risk of lymphoma requires further elucidation. Further,
the ability to follow-up, confirm, and extend these observations in the
United States is limited by the low prevalence and limited range of
several important chemical and viral exposures and the high to complete
linkage disequilibrium among key candidate genetic loci in Western
populations. To optimize the ability to build on and clarify these
findings, it is necessary to investigate populations that differ from
those in the West in both exposure patterns and underlying genetic
structure. A multidisciplinary case-control study of lymphoma in Asia,
where lymphoma rates have also risen, provides an opportunity to
replicate and extend recent and novel observations made in studies in
the West in a population that is distinctly different with regard to
patterns of key risk factors, including range of exposures, prevalence
of exposures, correlations between exposures, and variation in gene
regions of particular interest. It will also improve the ability to
understand the causes of certain types of rare lymphoma tumors in the
United States that occur at much higher rates in Asia. As such,
AsiaLymph will confirm and extend previous findings and yield novel
insights into the causes of lymphoma and leukemia in both Asia and in
the United States. The major postulated risk factors for evaluation in
this study are chemical exposures (i.e.,
[[Page 52326]]
organochlorines, trichloroethylene, and benzene) and genetic
susceptibility. Other factors potentially related to lymphoma, such as
viral infections, ultraviolet radiation exposure, medical conditions,
and other lifestyle factors will also be studied. Patients from 11
participating hospitals will be screened and enrolled. There will be a
one-time computer-administered interview, and patients will also be
asked to provide a one-time blood and buccal cell mouth wash sample and
lymphoma cases will be asked to make available a portion of their
pathology sample.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 3,086.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Time per
Types of respondents Instrument Number of Frequency of response Annual burden
respondents response (hours) hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Potential Study Subjects....................... Screening Questions.................... 1,804 1 5/60 150
Consented Patient Cases........................ Core Questionnaire & Occupational Job 967 1 105/60 1,692
Module.
Consented Patient Controls..................... Core Questionnaire & Occupational Job 300 1 105/60 525
Module.
Study Pathologists............................. Pathology sample request and tracking 10 97 5/60 81
form.
Interviewers................................... Tracking forms......................... 15 85 30/60 638
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: August 24, 2015.
Karla Bailey,
Project Clearance Liaison, National Cancer Institute, NIH.
[FR Doc. 2015-21273 Filed 8-27-15; 8:45 am]
BILLING CODE 4140-01-P
